Breaking Down SG&A Expenses: Corcept Therapeutics Incorporated vs ADMA Biologics, Inc.

A Comparative Analysis of SG&A Expenses: Corcept Therapeutics vs. ADMA Biologics

In the competitive landscape of biotechnology, understanding the financial strategies of leading companies is crucial. Over the past decade, Corcept Therapeutics Incorporated and ADMA Biologics, Inc. have demonstrated distinct approaches in managing their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Corcept Therapeutics consistently outpaced ADMA Biologics, with SG&A expenses growing from approximately $35 million to $184 million, marking a staggering 426% increase. In contrast, ADMA Biologics saw a more modest rise from $4.8 million to $59 million, a 1,125% increase, albeit from a smaller base. This trend highlights Corcept's aggressive expansion and investment in administrative capabilities, while ADMA's growth reflects its strategic scaling efforts. As these companies continue to evolve, their financial strategies will play a pivotal role in shaping their market positions.